Elicera Therapeutics AB (publ) (STO: ELIC)

Elicera Therapeutics AB Statistics

Total Valuation

Elicera Therapeutics AB has a market cap or net worth of SEK 61.41 million. The enterprise value is 30.78 million.

Market Cap	61.41M
Enterprise Value	30.78M

Important Dates

The last earnings date was Friday, November 29, 2024.

Earnings Date	Nov 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Elicera Therapeutics AB has 35.09 million shares outstanding. The number of shares has increased by 39.67% in one year.

Current Share Class	n/a
Shares Outstanding	35.09M
Shares Change (YoY)	+39.67%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	28.76%
Owned by Institutions (%)	12.14%
Float	23.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.31
PB Ratio	2.63
P/TBV Ratio	2.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.69
EV / Sales	7.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.02

Current Ratio	4.02
Quick Ratio	4.02
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-418.20

Financial Efficiency

Return on equity (ROE) is -82.01% and return on invested capital (ROIC) is -53.87%.

Return on Equity (ROE)	-82.01%
Return on Assets (ROA)	-40.47%
Return on Capital (ROIC)	-53.87%
Revenue Per Employee	2.14M
Profits Per Employee	-9.13M
Employee Count	2
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.36% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-64.36%
50-Day Moving Average	1.77
200-Day Moving Average	1.59
Relative Strength Index (RSI)	51.03
Average Volume (20 Days)	164,114

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Elicera Therapeutics AB had revenue of SEK 4.29 million and -18.26 million in losses. Loss per share was -0.66.

Revenue	4.29M
Gross Profit	4.29M
Operating Income	-19.19M
Pretax Income	-18.26M
Net Income	-18.26M
EBITDA	-19.18M
EBIT	-19.19M
Loss Per Share	-0.66

Balance Sheet

Cash & Cash Equivalents	30.63M
Total Debt	n/a
Net Cash	30.63M
Net Cash Per Share	0.87
Equity (Book Value)	23.37M
Book Value Per Share	0.67
Working Capital	23.37M

Cash Flow

Operating Cash Flow	-15.73M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-447.76%
Pretax Margin	-426.04%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Elicera Therapeutics AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-39.67%
Shareholder Yield	-39.67%
Earnings Yield	-37.91%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Elicera Therapeutics AB has an Altman Z-Score of 0.85. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.85
Piotroski F-Score	n/a